

CURRENT REPORT 35/2024
November 29, 2024

Recommendation of Ryvu's project for funding by the Małopolska Centre for Entrepreneurship

The Management Board of Ryvu Therapeutics S.A. with its registered office in Kraków ("Company"), informs that on November 29th, 2024 it became aware of the inclusion of the Company's project titled "InfraADC - Research infrastructure enabling R&D activities on Antibody-Drug Conjugates (ADC) as next generation targeted therapies in oncology ("Project") on the ranking list of projects recommended for funding under call no. FEMP.01.03-IP.01-017/24, Priority 1. European Funds for research, development and entrepreneurship, Action 1.3 Research and development infrastructure of enterprises, Project type A. R&D infrastructure of enterprises, under the European Funds for Małopolska 2021-2027 organised by the Małopolska Centre for Entrepreneurship ("MCP"). The recommendation for funding was confirmed by Resolution No. 2528/24 of the Małopolska Regional Government Board dated November 27, 2024.

The aim of the Project is to implement new technologies, not used by the Company so far, and the required adaptation of DMPK (bioanalytical), biochemical and biological laboratories. As part of the Project, the Company plans to acquire specialized research equipment as well as control and support software for these devices. The acquired equipment will enable work on Antibody-Drug Conjugate (ADC) technology. Within the scope of the planned R&D activities, the Company intends to initiate new production processes, understood as research processes for the discovery and development of innovative oncology drugs, and to expand its product portfolio with ADC projects in oncology.

The Project obtained the highest number of ranking points among all submitted applications, ex aequo with several other projects.

- the total value of the Project is: PLN 7,523,159.70;
- recommended amount of the funding: PLN 3,085,312.00;
- assumed Project implementation period: 24 months.

In case the funding agreement is concluded and the Project is implemented, the granted funding may limit the use of the Company's own funds.

The Company will announce the conclusion of the relevant funding agreement with MCP, as well as other significant events related to the Project, in the form of current reports.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board